Title : Molecular mechanisms underlying the anti-atherogenic actions of probiotics
Abstract:
Atherosclerosis, a chronic inflammatory disease of medium and large arteries, is the leading cause of myocardial infarction and cerebrovascular accidents, accounting for more global deaths than any other condition. Although lifestyle modifications and pharmacotherapies have reduced morbidity and mortality, the growing prevalence of risk factors such as hypercholesterolemia, obesity and diabetes threatens to reverse these gains. Current treatments leave substantial residual cardiovascular risk and are often associated with adverse effects, while many promising pharmaceutical leads have failed in clinical trials.
A deeper understanding of the molecular basis of atherosclerosis is essential for developing novel preventive and therapeutic strategies. Our research focuses on elucidating the mechanisms underlying the anti-atherogenic effects of natural products using integrated in vitro and in vivo models combined with biochemical, molecular and immunological approaches. These studies have revealed novel insights into the protective actions of several nutraceuticals. This presentation will highlight he molecular basis of atherosclerosis, limitations of current therapies, emerging approaches targeting lipid metabolism and inflammation, and the potential of probiotic bacteria as preventive and therapeutic agents
